Mutations in the IDH1 gene were the first detectable genetic alterations in glioblastomas, and the mutated IDH protein is thought to have a relatively good prognosis by competitively inhibiting participation in histone and DNA demethylation, thereby blocking cell differentiation and reducing tumor cell proliferation.3, 4, 5 Accurate prediction of glioma IDH1 mutation before treatment is of great significance to guide individualized treatment and prognosis assessment, which has become a research hotspot in radiogenomics in recent years.6 The gene discussed is IDH1; the disease is neoplasm.